incretins

News

GLP-1 drugs linked to reduced acute schizophrenia episodes

The list of illnesses that may benefit from treatment with GLP-1 drugs gets ever longer, and a study has found that schizophrenia may be an addition.

News

Lilly's Zepbound enhances Taltz efficacy in psoriasis study

A study has shown that the efficacy of Lilly's psoriasis therapy Taltz is improved when it is given in combination with weight-loss drug Zepbound.

News

Graphic of faceless person with board in front of them reading Coming Soon on orange background

UK watchdog takes first action on oral weight drug adverts

Online pharmacies operating in the UK breached Advertising Standards Authority rules by promoting oral weight drugs to the public.

News

Lilly fleshes out triple G data in diabetes and obesity

Eli Lilly has revealed more data with its triple G agonist retatrutide, boosting its credentials as the next big thing in cardiometabolic diseases.

News

Novo turns to Hengrui for another oral obesity drug

Novo has agreed to pay up to $2.6 billion for rights to a weight-loss pill, developed by China's Hengrui Pharma, that could be dosed just once a week.

News

Novo Nordisk's IL-6 drug flunks two more heart trials

Novo Nordisk has opted to discontinue two late-stage trials of IL-6 inhibitor ziltivekimab in heart failure, after taking an interim look at the data.

GLP-1 drugs linked to reduced acute schizophrenia episodes

Lilly's Zepbound enhances Taltz efficacy in psoriasis study

UK watchdog takes first action on oral weight drug adverts

Lilly fleshes out triple G data in diabetes and obesity

Novo turns to Hengrui for another oral obesity drug

Novo Nordisk's IL-6 drug flunks two more heart trials

Compounded tirzepatide recalled after FDA warning

Discover a new era of healthcare panel engagement: Grounded ...

incretins

Editor's Picks